Claritas Pharmaceuticals Inc V.CLAS.H

RE:RE:RE:Folks if you do not have plans to buy more shares yur

[Captainblk]

quote=AngelaLSaNOtize is making a noble effort to leverage the ability of nitric oxide to kill COVID-19 but the company's product cannot compete against Kalytera'a R-107. Why? Two reasons: 1) SaNOrize uses acidified nitrite to generate nitric oxide from the nasal spray while in the nose. The stuff has to be really acidic to turn nitrite into nitric oxide. Have you ever tried putting acid up your nose? saNOtize will not be a terribly pleasant or popular product to use!
I think its not as bad as you are trying to sell it as. most of us deal with acid on a daily basis (pop, OJ, lemon juice, apple juice, coffee) so throwing around a scary word like acid doesnt mean much. It might not feel great, but neither does ANY fluid in your nose. Think of a Nettypot.


2) SaNOtize will generate nitric oxide for at most a few minutes after the acid is added. Whereas, R-107 enters cells as an organic nitrate where it is converted slowly to nitric oxide. So it should work for many hours. Bottom line: SaNOtize has little chance of medical or commercial success.
This is taken DIRECTLY from Claritas Pharmas website which is just about to go live, so one would assume it's the most up to date information they can provide: FAQ - Claritas Pharmaceuticals (googleusercontent.com)

HOW IS NITRIC ACID ADMINISTERED TO COVID -19 PATIENTS?
Nitric oxide is a gas that is administered to intubated patients through use of a specialized breathing device. The drug must be administered by a trained respiratory therapist, and it must be administered twice daily.

IS NITRIC ACID GAS A PRACTICAL TREATMENT FOR WIDESPREAD COVID-19 INFECTION?
No, nitric oxide gas must be administered as an inhalation therapy requiring special CPAP-like delivery equipment and administration by a trained respiratory therapist twice per day, which substantially limits the number of patients that can be treated at any one time. As such, nitric oxide is not a practical treatment in a pandemic situation.


From their own website they are saying that what they offer is not a practical solution, and you are saying that SaNOTIZE will not see medical or commercial success? I think that is a bold statement which contradcts what the company themselves state. 

compare them to SaNOtize:

At present, SaNOtize:

• Has received Health Canada approval and initiated a multi-center, randomized, controlled, phase II efficacy study (N=210) evaluating NORS TM for the prevention and treatment of COVID-19 in healthcare workers and individuals at risk of infection;
• Has confirmed that NORSTM is >99.9% effective against different types of coronaviruses (including SARS-CoV-2, the virus that causes COVID-19) in tests conducted by the independent Institute for Antiviral Research at Utah State University;
• Has applied to the FDA for Emergency Utilization Authorization in adults  with an emphasis on availability for healthcare workers; and
• Is working on an IND to allow a clinical trial in the US

KLY/CLARITAS HAS:

A Patent:
R-107 has issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea. The patents covering use of R-107 in treatment of COVID-19 should provide patent protection through at least 2045

(another)agreement with Salzman group:
Claritas will enter into a strategic collaboration with the Salzman Group, under which the Salzman Group will make available to Claritas the full capabilities of Salzman Group, including their deep expertise in working with nitric oxide and nitric oxide releasing compounds

(another)Private Placement with Echelon to fund a yet started Phase 1 Study:

• Estimated Cost of Phase 1 Clinical Study: The estimated cost of the Phase 1 study is CAD $1,040,000. Claritas will work with Echelon Wealth Partners to complete a private placement financing to fund the R&D cost of the Phase 1 study, as well as funding for 12-months of G&A expense

A plan to ask for Gov't Funds once Phase 1 is complete:
Follow-On Clinical Studies: Following completion of the Phase 1 study, Claritas intends to apply for funding from the U.S. Department of Health and Human Services for the further development of R-107 in COVID-19 infection